Researchers at University of California, San Diego School of Medicine have received a five-year, $9.5-million award from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH) to establish an interdisciplinary center to define the systems biology of antibiotic resistance. The program will be led by Bernhard Palsson, PhD, Distinguished Professor of Bioengineering and Pediatrics, and Victor Nizet, MD, professor of pediatrics and pharmacy.
Bacteria that no longer reliably respond to antibiotic therapy, so-called "superbugs," pose one of the greatest threats in modern medicine. Superbugs, such as methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile (C. diff), and carbapenem-resistant Enterobacteriaceae (CRE), often strike hospitalized patients, the elderly or those with weakened immune systems or chronic medical conditions. The U.S. Centers for Disease Control and Prevention estimate that at least 2 million Americans become infected with antibiotic-resistant bacteria and at least 23,000 people die each year as a direct result of these infections.
"I worry that approaches currently used in the clinic to evaluate antibiotic activity are antiquated and simplistic, and address the drug's action only on bacteria growing in artificial laboratory media without attention to the human immune system," Nizet said. "Our research has shown that certain antibiotics can synergize with the natural defenses of our immune system to clear infections in a way that wouldn't have been predicted by current testing paradigms."
Palsson is a leader in the emerging field of systems biology, which explores the complexity of living systems — from the genome to the entire organism — using experimental and computational methods. Concerned by the exploding problem of drug-resistant bacterial pathogens, Palsson reached out to Nizet, a physician-scientist, to explore whether systems-level approaches could be coupled with experimental models of antibiotic drugs, living bacterial pathogens, human immune cells and animal models of infection to benefit patients with antibiotic-resistant infections.
"Dr. Nizet's work demonstrates how unexpected environmental factors influence the efficacy of antibiotics. Thus, improving treatment outcomes in serious or antibiotic-resistant bacterial infection will require systems-level analyses at the molecular level," said Palsson. "We could paraphrase and honor geneticist and evolutionary biologist Theodosius Dobzhansky's famous quote by saying: 'Nothing in biology makes sense, except in the light of systems thinking.'"
"By bringing together researchers from our School of Medicine, Skaggs School of Pharmacy and Pharmaceutical Sciences and Jacobs School of Engineering, this new center embodies the collaborative, interdisciplinary spirit for which UC San Diego is known," said David Brenner, MD, vice chancellor of UC San Diego Health Sciences and dean of UC San Diego School of Medicine. "We're grateful to the NIH for recognizing our leading-edge capabilities in medicine, engineering and computer science, and for supporting researchers ambitious and talented enough to take on one of the greatest global medical challenges of our time."
Modified darobactin offers hope for combatting antibiotic-resistant bacteria